

Imatinib Teva is indicated for the treatment of

- **Paediatric patients with newly diagnosed Philadelphia chromosome (bcrabl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.**
- **Paediatric patients with Ph+ CML in chronic phase after failure of interferonalph therapy, or in accelerated phase or blast crisis.**
- **Adult patients with Ph+ CML in blast crisis.**

The effect of imatinib on the outcome of bone marrow transplantation has not been determined.

In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progressionfree survival in CM.

Marketing Authorisation Holder:

**Teva
Pharma
B.V.**